Beta Drugs Ltd

- Beta Drugs Limited has recently completed a fundraising of INR117 crores from marquee investors, including HealthQuad, Tanas Capital, and a generational capital fund. - The funds raised are primarily earmarked for future growth initiatives: state-of-the-art R&D facilities (formulation and API), establishment of an intermediate plant, and venturing into recombinant proteins. - There was no indication of any additional current or future fundraising through debt or equity during this conference call. - The company is focusing on using internal accruals for regular capex around INR10-12 crores in FY26. - No new fundraising beyond the mentioned INR117 crores was discussed.

- Planned capex for FY26 excluding new projects: INR 10-12 crores from internal accruals. - Fundraise of INR 117 crores for strategic investments: - Establishing a state-of-the-art combined R&D facility (formulation + API) with INR 10-15 crores capex. - Setting up an intermediate plant with an investment of INR 15-20 crores to reduce dependence on China and support API production. - Future venture into recombinant proteins and biosimilars. - R&D expense expected to rise from current 2-3% to 4-5% post new facility. - Expansion in intermediate production aims to boost margins by 10-15% and cater initially to internal API requirements. - Plans for EU-GMP and Mexico COFEPRIS audits to enable regulated market entry.

- Overall company growth targeted at 25% to 30% annually for the coming years. - Export business expected to grow around 50% annually over the next 3-4 years, with focus on gaining registrations and entering EU and US markets. - Domestic cytotoxic market expected to grow at a CAGR of 15-20%, reaching about INR 4,000-5,000 crores by 2028-2030. - CDMO business to show steady growth with increasing sales in the second half of FY25; current first half sales around INR 72.7 crores. - Derma segment to double revenue next financial year, reaching INR 26-30 crores with new product launches and expanded prescriber network. - Intermediate production facility will boost internal API margins by 10-15%. - R&D focused on launching 20-25 products and developing new NDDS and biosimilar molecules over the next 2-3 years.

- Beta Drugs expects total company growth at 25%-30% over the next few years, with exports growing even faster. - Export business is projected to grow around 50% annually for the next 3-4 years, aided by new registrations and dossier filings. - API business is a key focus with plans for DMF filings and entry into regulated markets; currently exports in API are negligible but expected to grow. - CDMO business sales showed 2%-5% growth H1 FY25, with expectations of steady and better sales in the next half. - Derma segment aims to double sales to around INR26-30 crores next financial year with product launches and new prescriber additions. - EBITDA margins expected to be around 22%-26% depending on segment; export margin is around 23%-26%. - Intermediate plant investment (~INR15-20 crores) to boost margins by 10%-15%. - Fundraise (~INR117 crores) targeted at R&D, intermediate facility, and recombinant proteins to drive future earnings growth.

- The transcript does not explicitly mention the current or expected order book or pending orders for Beta Drugs Limited. - However, management indicates a strong pipeline with plans to launch 5 new molecules and NDDS by next year. - The company is experiencing significant growth in exports with a 141% increase, supported by new registrations and dossier filings. - CDMO business growth is steady with all CDMO partners retained and expected sales to improve in the second half. - Intermediate manufacturing facility investment of INR15-20 crores aims to boost internal API production, potentially increasing margins by 10-15%. - Expanding regulatory capabilities and approvals (EU-GMP, COFEPRIS, ZAZIBONA) indicate a growing ability to secure international contracts/orders. - Overall, while exact order book numbers are not stated, the company projects strong demand and growth across multiple verticals driven by regulatory registrations and new product launches.